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Abstract. An algorithm for dynamic multileaf-collimator (dMLC) tracking of a8
target performing a known a priori, rigid-body motion during volumetric modulated9
arc therapy (VMAT), has been experimentally validated and applied to investigate10
the potential of the Agility (Elekta AB, Stockholm, Sweden) multileaf-collimator for11
use in motion-compensated VMAT delivery. For five VMAT patients, dosimetric12
measurements were performed using the Delta4 radiation detector (ScandiDos,13
Uppsala, Sweden) and the accuracy of dMLC tracking was evaluated using a gamma-14
analysis, with threshold levels of 3% for dose and 3 mm for distance-to-agreement. For15
a motion trajectory with components in two orthogonal directions, the mean gamma-16
analysis pass rate without tracking was found to be 58.0%, 59.0% and 60.9% and17
was increased to 89.1%, 88.3% and 93.1% with MLC tracking, for time periods of18
motion of 4 s, 6 s and 10 s respectively. Simulations were performed to compare the19
efficiency of the Agility multileaf-collimator with the MLCi multileaf-collimator when20
used for motion-compensated VMAT delivery for the same treatment plans and motion21
trajectories. Delivery time increases from a static-tumour to dMLC tracking VMAT22
delivery were observed in the range 0%-20% for the Agility, and 0%-57% with the23
MLCi, indicating that the increased leaf speed of the Agility MLC is beneficial for24
MLC tracking during lung radiotherapy.25
1. Introduction26
Dynamic multileaf-collimator (dMLC) tracking as a research interest has led to the27
development of prototype real-time MLC tracking systems for both Siemens (Tacke28
et al. 2010, Krauss et al. 2011, Krauss et al. 2012) and Varian (Sawant et al. 2008, Keall29
et al. 2011, Poulsen et al. 2012a) linear accelerators. It is currently not possible to30
use Elekta linear accelerators for real-time dMLC tracking, however the feasibility of31
conformal dMLC tracking of a target performing a known a priori motion trajectory32
has previously been investigated by McQuaid et al. (2009). In the absence of a real-33
time MLC tracking system for Elekta linear accelerators, an algorithm for tracking34
motion known a priori has previously been presented (Davies et al. 2011). In the35
study presented in this paper, the algorithm is applied to and experimentally validated36
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for the latest Elekta multileaf-collimator, Agility (Elekta AB, Stockholm, Sweden), for37
MLC tracking during volumetric modulated arc therapy (VMAT) (Otto 2008, Yu &38
Tang 2011). Few studies so far have investigated the capabilities of the Agility MLC39
(Cosgrove et al. 2009, Bedford et al. 2013) and the authors believe a study of its40
suitability for MLC tracking is timely.41
The Agility MLC has 160 leaves, of projected leaf width 5 mm at the isocentre,42
arranged in two banks of 80 leaves. Each bank of leaves is contained within a dynamic43
leaf guide (DLG), which can move with the MLC leaves. The maximum velocity of44
the individual MLC leaves is 35 mm s−1, and for the dynamic leaf guide, 30 mm s−1,45
therefore the maximum possible velocity, if both the dynamic leaf guide and the MLC46
leaves are moving in the same direction, is 65 mm s−1. There are two jaws that move47
perpendicular to the direction of MLC leaf travel, and these have a maximum velocity48
of 90 mm s−1. These increased leaf and jaw velocities compared with previous Elekta49
multileaf-collimator models, such as the MLCi with a maximum leaf speed of 20 mm s−1,50
could confer advantage for dMLC tracking during VMAT delivery, as is investigated in51
this paper.52
The aim of this study was to experimentally validate the algorithm presented53
by Davies et al. (2011) for its ability to successfully predict the machine parameters54
during static-tumour and MLC-tracking VMAT delivery with the Agility MLC, and55
then to apply this algorithm to investigate the potential of the Agility MLC for56
motion-compensated VMAT delivery. Dose measurements were performed to determine57
the dosimetric accuracy of this MLC-tracking technique using the Delta4 diode-array58
phantom, which has previously been evaluated for IMRT and VMAT verification by59
Bedford et al. (2009). A motion-platform purpose-built in-house for translating the60
Delta4 phantom in three-dimensions was used to simulate target motion. Additionally,61
through simulations, the delivery-time efficiency for tracking with the Agility multileaf-62
collimator compared with the previous generation multileaf-collimator, the MLCi, was63
evaluated for the same VMAT plans and motion trajectories.64
2. Method65
2.1. VMAT treatment plans66
VMAT treatment plans for five lung cancer patients were prepared for the Agility MLC67
using AutoBeam v5.2, an in-house treatment planning system (Bedford 2009, Bedford68
2013). The plans generated were conformal arcs, i.e. the MLC leaves conform to the69
planning target volume but the prescribed monitor units per segment (i.e. the interval70
between two neighbouring control points) vary. A case study of the VMAT planning71
process using AutoBeam has previously been presented (Bedford et al. 2008).72
Each plan had a control point spacing of 5 ◦, with a 350 ◦ arc ranging from 185 ◦ to73
175 ◦ degrees. The collimator angle for each plan was 0 ◦. When implemented clinically, a74
collimator of angle of 2 ◦ - 5 ◦ degrees would be used, but this was removed for simplicity75
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when transforming the MLC leaf positions to account for motion. A summary of the76
key parameters for each VMAT plan is given in table 1. In order to provide information77
regarding the complexity of each treatment plan, the minimum and maximum values78
of gantry speed, dose rate and prescribed monitor units per segment is presented. The79
variation in gantry speed and dose rate was measured during delivery of each treatment80
plan on the linear accelerator used for the experiments presented in this study. It should81
be noted that the nominal maximum gantry speed of the linear accelerator is 6.0 ◦ s−1,82
however the transient gantry speed sometimes exceeds this, as is observed in table 1.83
Table 1. Key parameters of the VMAT treatment plans used in this study. Values
presented are for static-tumour, i.e. without motion-compensation, VMAT delivery.
Range (min - max)
Patient Prescribed Monitor MU per Gantry speed† Dose rate†
number dose (Gy) units (MU) segment (◦ s−1) (MU s−1)
1 2.75 348.0 4.8 - 5.2 5.7 - 6.5 5.45 - 5.98
2 2.75 374.9 4.5 - 6.2 5.1 - 6.4 5.17 - 6.90
3 2.75 408.1 5.2 - 6.4 5.2 - 6.5 5.95 - 7.42
4 1.75 249.1 2.5 - 4.9 5.3 - 6.5 2.87 - 5.62
5 2.75 363.1 1.6 - 9.1 5.1 - 6.8 1.78 - 9.13
† Measured data during delivery on linear accelerator.
2.2. Simulation of a respiratory motion trajectory84
A two-dimensional Lujan et al. (2003) respiratory-motion trajectory was modelled of85
the form:86
ztarget(t) = z0 − Az cos6
(
pit
τ
+
pi
2
)
(1)
ytarget(t) = y0 + Ay cos
6
(
pit
τ
+
3pi
5
)
(2)
where ztarget(t) is the motion along the z-axis and ytarget(t) is the motion along the87
y-axis. z0 and y0 are the rest positions of the target motion (taken to be zero in this88
study), Az is the amplitude of motion in the z direction and is equal to 20 mm and Ay89
is the amplitude of motion in the y direction and is equal to 10 mm. The time period90
is given by τ , and was varied to be either 10 s, 6 s or 4 s in this set of experiments. A91
motion platform designed and built in-house for the translation of the Delta4 phantom in92
three-dimensions, and accurate to within 0.2 mm using a Galil DMC-4060 (Galil Motion93
Control, Inc., Rocklin, CA, USA) motion controller, was programmed to move with the94
trajectory described by (1) and (2). The experimental set-up and the orientation of the95
axes of motion with respect to the linear accelerator are shown in figure 1.96
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Figure 1. Photograph of the experimental set-up: the motion platform carrying the
Delta4 is shown mounted on the linear accelerator couch. The orientation of the axes
of motion are labelled in red.
2.3. MLC tracking algorithms97
A VMAT arc is defined as a series of N control points (n = 1, 2, 3, ..., N), and a segment98
m is defined as the interval between two neighbouring control points, n and n + 1.99
The total number of segments (m = 1, 2, 3, ...,M) is given by N − 1. The algorithm100
presented by Davies et al. (2011) compensates for a priori known motion by transforming101
the planned MLC leaf positions at each control point, and iteratively reducing the dose102
rate of each segment of the VMAT arc until the MLC tracking plan is deliverable i.e.103
machine constraints such as maximum leaf velocity and maximum gantry velocity are not104
violated. In this study, the algorithm was applied to the Integrity 3.0 control system, in105
which the dose rate can vary by 256 levels, from 0 to the maximum. For motion parallel106
to the direction of leaf travel the positions of the k MLC leaves, at control point n, zkn ,107
were transformed using:108
z
′
kn = zkn + f‖n (3)
where for a collimator angle of 0 ◦, the correction required, f‖n is given by:109
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Figure 2. Schematic illustrating the linear-interpolation technique for transforming
the MLC aperture to account for motion perpendicular to the direction of leaf travel.
f‖n = ytarget
(
t =
n−1∑
m=1
tm
)
sin θ (4)
where tm is the segment time and θ is the gantry angle, which varies from 0
◦ to110
359 ◦.111
For motion perpendicular to the direction of leaf travel, which was not considered in112
the initial study by Davies et al. (2011), the MLC leaf positions were transformed using a113
linear-interpolation technique. This involved refitting the MLC leaves to a new contour114
which was derived from transforming the static MLC aperture contour to account for115
motion perpendicular to the direction of leaf travel. In this study, the centre of each116
MLC leaf edge was fitted to its intercept with the new, transformed aperture contour;117
this is illustrated in figure 2. The contour shift at control point n, perpendicular to the118
direction of leaf travel, f⊥n , is given by:119
f⊥n = ztarget
(
t =
n−1∑
m=1
tm
)
(5)
The jaws (denoted Y1 and Y2) that move perpendicular to the direction of leaf120
travel were also transformed to account for motion using:121
Y
′
jawn = Yjawn + f⊥n (6)
An example of the aperture transformation, parallel and perpendicular to the122
direction of leaf travel, at a particular control point for patient 1 is shown in figure 3.123
It should be noted that in this study, the direction of motion of the MLC leaves was124
perpendicular to the motion axis with the largest amplitude, as given by (1). Clinical125
VMAT plans at our centre are planned in this way, with a collimator rotation close to 0 ◦.126
This has the advantage of maximising the number of leaves used to create the treatment127
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aperture as the apertures are typically elongated in the z-direction and therefore the128
distance between adjacent MLC leaves at each control point is minimised.129
2.4. Experimental validation of the MLC tracking algorithm with the Agility MLC130
The algorithm requires knowledge of certain machine parameters to calculate the static-131
tumour VMAT and dMLC tracking VMAT delivery. These parameters are given in132
table 2. It should be noted that if all the MLC leaves are moving in the same direction,133
it is possible for the combined maximum velocity of the MLC leaves and the DLG to134
be 65 mm s−1. However, the main purpose of the dynamic leaf guide is to increase the135
travel range of the MLC leaves. Therefore, as the VMAT plans used in this study, both136
static and tracking, required leaf motion between control points typically less than or137
equal to 20 mm and of an oscillatory nature, the DLG remained stationary. Therefore138
the maximum leaf velocity was taken to be 35 mm s−1.139
Table 2. Machine constraints of the Elekta Synergy linear accelerator used for the
measurements.
Machine parameter Nominal maximum value
Gantry speed (◦ s−1) 6
Gantry inertial compensation distance (◦) 5
Dose rate (MU s−1) 9.25
MLC leaf velocity (mm s−1) 35
DLG velocity (mm s−1) 30
Jaw velocity (mm s−1) 90
To determine the ability of the algorithm to correctly predict the linear accelerator140
parameters during static-tumour and dMLC VMAT tracking delivery, a logging function141
on the Elekta linear accelerator control system was used to record the dose rate during142
each static-tumour and dMLC tracking VMAT delivery. The real-time delivery time,143
i.e. that measured from the logging function, was compared with the simulated delivery144
time and the time difference in seconds compared. Additionally, the simulated and145
real-time dose rates were compared as a function of monitor units for each plan.146
2.5. Evaluation of the accuracy of dMLC tracking147
For each VMAT plan six dose distributions were measured with the Delta4 phantom:148
(i) Static-tumour VMAT plan with static Delta4149
(ii) Static-tumour VMAT plan with motion platform translating Delta4 in 1D150
(iii) Static-tumour VMAT plan with motion platform translating Delta4 in 2D151
(iv) 1D MLC tracking VMAT plan with motion platform translating Delta4 in 1D152
(v) 1D MLC tracking VMAT plan with motion platform translating Delta4 in 2D153
(vi) 2D MLC tracking VMAT plan with motion platform translating Delta4 in 2D154
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Figure 3. A diagram showing the beam’s-eye-view of the MLC aperture, at a gantry
angle of 90 ◦, for patient 1. The MLC leaves are shown in blue, and the position of the
jaws that move perpendicular to the direction of leaf travel, Y1 and Y2, are shown in
red. (a) shows the MLC aperture for the static-tumour VMAT plan and (b) shows the
MLC aperture for the 2D MLC tracking VMAT plan with 10 s time period, where the
aperture has been transformed for motion along the z-axis and the y-axis. The axes
of target motion are labelled in green. The Agility MLC has a total area of 400 mm
× 400 mm, but only the inner 200 mm × 200 mm area is shown here.
MLC tracking with the Agility MLC 8
where static-tumour VMAT plans are those created by the treatment planning155
system, 1D MLC tracking VMAT plans are those where the MLC leaf positions have156
been adjusted to follow the primary axis of motion in this study (given by (1)), and 2D157
MLC tracking VMAT plans refer to plans following motion along both axes of motion158
(given by (1) and (2)).159
Dose distributions (ii) and (iv) were acquired with the motion platform translating160
the Delta4 with the motion trajectory given by (1) and dose distributions (iii), (v) and161
(vi) were acquired with the motion platform translating the Delta4 with the motion162
trajectory given by both (1) and (2). Dose distributions (ii) - (vi) were compared to163
the reference dose distribution (i) by means of a gamma analysis with a threshold of 3%164
and 3 mm. Detectors that were outside of the 5% isodose level for the reference dose165
distribution (dose distribution (i)) were not included in the gamma analysis. This was166
repeated for each of the three time periods of motion investigated in this study. For167
reference, the dose distribution calculated by the treatment planning system (TPS) for168
the Delta4 geometry was also compared with dose distribution (i) and evaluated using169
a gamma analysis with threshold levels of 3% and 3 mm, excluding detectors outside of170
the 20% isodose level, as per clinical practice.171
There is a finite start-up time between the user initiating the VMAT arc on172
the control system, and the radiation beam. Therefore, in order to synchronise the173
movement of the Delta4 phantom with gantry movement and thus MLC leaf positions,174
an optical gating interface was used. The start-up time was determined to be 1.5 s, and175
therefore as the user initiated the VMAT arc, the motion of the Delta4 was triggered,176
but delayed by 1.5 s to remove this latency.177
2.6. Evaluation of the delivery efficiency of MLC tracking with the Agility and MLCi178
multileaf-collimators179
Simulations were performed to compare the increase in delivery time from a static-180
tumour VMAT delivery to a 1D and 2D MLC tracking delivery for the Agility MLC181
and the MLCi MLC. The MLCi has a lower maximum leaf velocity of 20 mm s−1, and a182
lower maximum jaw velocity. The MLCi jaws that move parallel to the direction of leaf183
travel have a maximum velocity of 20 mm s−1 and those that move perpendicular have a184
maximum velocity of 15 mm s−1. Another major difference is that the MLCi has a leaf185
width at isocentre of 10 mm, double that of the Agility. However, it was not possible to186
repeat the experiments performed with the Agility to determine the dosimetric effect of187
this increased leaf width, as a linear accelerator with an MLCi multileaf-collimator and188
a version of the Integrity control system was not available at our centre.189
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3. Results190
3.1. Experimental validation of the MLC tracking algorithm with the Agility MLC191
The simulated versus real-time dose rate as a function of monitor units for two of the192
patients is shown in figure 4. The static-tumour VMAT deliveries are shown in figures193
4(a) and 4(c), and the corresponding 2D MLC tracking deliveries, for a time period of194
4 s, are shown in figures 4(b) and 4(d). It can be seen that in general, the algorithm195
correctly predicts the dose rate bin for each segment of the VMAT plan, and the same196
was observed for all plans measured. The simulated versus real-time delivery time for all197
plans measured in this set of experiments is shown in figure 5. The agreement with the198
line of equality as given by Lin’s concordance correlation coefficient (Lin 1989) was found199
to be 0.914, indicating strong correlation between the algorithm’s predicted value and200
the measured value. However, it can be seen that the algorithm always underestimates201
the real-time delivery time. This is due to the fact that the algorithm assumes that the202
required dose rate bin is reached instantaneously and that the dose rate remains constant203
at this value for the duration of the segment without fluctuations, which in practice is204
not the case. Additionally, unscheduled pauses in the treatment beam during the VMAT205
arc introduce residual time differences between the simulated and the real-time delivery.206
Such pauses can be seen in figures 4(a) and 4(c), at around 10 MU, where the dose rate207
drops to zero. In the absence of a real-time control system this leads to a degree of208
desynchronisation between actual motion and the resulting motion-compensation if this209
occurs during the MLC tracking VMAT deliveries.210
3.2. Evaluation of the accuracy of MLC tracking211
The results of the gamma analysis with threshold levels of 3% for dose and 3 mm for212
distance-to-agreement are shown in figure 6. Additionally, the results averaged over the213
five patient plans investigated in this study are presented in table 3. Figure 6 shows that214
for all patient plans, the use of MLC tracking, either 1D or 2D, has improved the gamma-215
analysis pass rate compared to the pass rate without tracking, and the improvement is216
most pronounced for the 10 s time period motion trajectory. This result is expected,217
as the differences in the simulated and real-time delivery due to the limitations of the218
model (discussed in the previous section) will be less important for the longer time219
period. For example, a 1 s time difference corresponds to a tenth of a breathing cycle220
for the 10 s tracking plans but will correspond to a quarter of a breathing cycle for221
the 4 s tracking plans. The results of the gamma-analysis reflect this; the mean pass222
rate for 1D tracking with 1D motion and 2D tracking with 2D motion is 93.0% and223
93.1% respectively for a 10 s time period, and is reduced to 84.2% and 89.1% for a 4 s224
time period. Additionally, it was found that the gamma analysis pass rate for the dose225
distribution calculated by the TPS for the Delta4 compared with the measured static226
dose distribution was found to be 100% for all patients.227
In general, the highest gamma-analysis pass rate is seen for the 1D tracking with228
MLC tracking with the Agility MLC 10
0 50 100 150 200 250 300 350
0
1
2
3
4
5
6
7
8
9
Monitor units
D
os
e 
ra
te
 (M
U 
s−1
)
 
 
Simulated delivery
Real−time delivery
(a)
0 50 100 150 200 250 300 350
0
1
2
3
4
5
6
7
8
9
Monitor units
D
os
e 
ra
te
 (M
U 
s−1
)
 
 
Simulated delivery
Real−time delivery
(b)
0 50 100 150 200 250 300 350 400
0
1
2
3
4
5
6
7
8
9
Monitor units
D
os
e 
ra
te
 (M
U 
s−1
)
 
 
Simulated delivery
Real−time delivery
(c)
0 50 100 150 200 250 300 350 400
0
1
2
3
4
5
6
7
8
9
Monitor units
D
os
e 
ra
te
 (M
U 
s−1
)
 
 
Simulated delivery
Real−time delivery
(d)
Figure 4. Dose rate as a function of monitor units for simulated and real-time VMAT
delivery. The dose rate for the static-tumour VMAT plans for patient 1 and patient 2
are shown in (a) and (c) respectively, and the corresponding 2D MLC tracking VMAT
plans (time period of 4 s) are shown in (b) and (d).
1D motion delivery and 2D tracking with 2D motion delivery, with some exceptions.229
During the experiments, if an unscheduled pause occurred in the VMAT arc, no attempt230
was made to repeat the arc until it delivered without pauses. The VMAT arc was only231
repeated if a fault brought the treatment to a premature end. Therefore any unscheduled232
pauses in the radiation beam resulted in the desynchronisation of the MLC leaf positions233
and the motion of the Delta4, and the acquired dose distribution still displayed minor234
motion-blurring. Therefore the gamma-analysis pass rate for certain tracking plans was235
reduced. For example, for patient 1 for a time period of 6 s, the 1D tracking with 1D236
motion delivery had the lowest gamma-analysis pass rate of all the tracking deliveries.237
The time difference between real-time and simulated delivery was 1.9 s for 1D tracking238
with 1D motion, 0.9 s for 2D motion with 1D tracking and 0.6 s for the 2D tracking239
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Figure 5. Comparison of the real-time delivery time and the simulated delivery time
for both static-tumour and MLC tracking plans for all patients.
with 2D motion delivery. Therefore, the first delivery with the largest time difference240
received the lowest gamma-analysis pass rate. For patient 5, for a 6 s time period, 1D241
tracking with 2D motion received the highest pass rate, and the same is observed for242
patient 2 for a 10 s time period. For patient 5, the time difference between simulated243
and real-time was 1.6 s for 1D tracking with 1D motion, 0.6 s for 1D tracking with 2D244
motion and 1.0 s for 2D tracking with 2D motion and the analogous time differences245
were 1.4 s, 0.6 s and 1.1 s for patient 2. This explains why 1D tracking with 2D motion246
had the highest pass rate for these examples.247
Despite these explicable discrepancies, the results show that when the VMAT arc248
is delivered smoothly without interruptions, the algorithm works well and a pass rate249
over 90% can be achieved, but unscheduled pauses are detrimental to the tracking250
dose distribution. For the sinusoidal motion studied here, with real-time control of the251
radiation beam, it would be possible to correct for the desynchronisation caused by252
these unscheduled pauses. For example, the breathing phase of the motion platform,253
and the corresponding breathing phase of the MLC leaf positions could be continually254
monitored, and if substantial desynchronisation is observed, the radiation beam could255
be paused until the correct phase is reached by the motion platform, at which point the256
beam could be reinitialised. However, such real-time control of the radiation beam was257
not available for this set of experiments, but would be desirable for further work with258
this algorithm.259
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Table 3. Gamma analysis results averaged over five patient plans. Numbers are
percentages, presented as mean ± standard deviation.
Gamma analysis percentage pass rate (3% and 3 mm)
1D motion 2D motion 1D motion 2D motion 2D motion
Time period (s) No tracking No tracking 1D tracking 1D tracking 2D tracking
4 60.3 ± 8.6 58.0 ± 6.9 84.2 ± 7.5 75.1 ± 2.8 89.1 ± 4.3
6 61.5 ± 7.9 59.0 ± 7.3 85.4 ± 9.9 88.3 ± 3.9 88.3 ± 7.4
10 62.9 ± 6.3 60.9 ± 7.4 93.0 ± 3.9 89.7 ± 4.2 93.1 ± 3.4
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Figure 6. Gamma analysis results from the dosimetric accuracy experiments with the
Delta4 radiation detector. A threshold level of 3% for dose and 3 mm for distance-
to-agreement was used, and detectors outside of the 5% isodose level in the reference
dose distribution were not included in the analysis.
3.3. Evaluation of the delivery efficiency of MLC tracking with the Agility and MLCi260
multileaf-collimator261
The results of the simulations performed to compare the delivery times of the MLCi262
multileaf-collimator and Agility multileaf-collimator for the same VMAT plans are263
shown in figure 7. It can be seen that the static-tumour VMAT delivery times are264
comparable for both the MLCi and the Agility MLC, but the Agility MLC is able to265
deliver the tracking plans in a shorter treatment time. In particular, for patients 3 to 5,266
the Agility MLC was able to deliver the tracking plans without an increase in delivery267
time, which was not possible with the MLCi MLC. For both multileaf-collimators, the268
largest percentage time increase was observed for the 2D MLC tracking VMAT plans269
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Figure 7. Simulated absolute delivery times for the static and tracking plans used
in this study for (a) the MLCi multileaf-collimator and (b) the Agility multileaf-
collimator.
for the shortest time period motion trajectory. The greatest percentage time increase270
observed from a static-tumour to MLC tracking delivery for the MLCi was 57%, for271
patient 1, and the analogous time increase for the Agility was 11%. It is clear that the272
Agility MLC leaf speed of 35 mm s−1 and increased jaw velocity, compared with the273
MLCi leaf speed of 20 mm s−1 and lower jaw velocity, is advantageous for MLC tracking,274
particularly with decreased time period of motion.275
4. Discussion276
In this study, a theoretical algorithm has been applied, experimentally, to evaluate277
MLC tracking during VMAT delivery on Elekta linear accelerators for the first time.278
VMAT MLC tracking experiments have also been performed and presented for Varian279
linear accelerators (Sawant et al. 2008, Zimmerman et al. 2009, Falk et al. 2010, Keall280
et al. 2011, Poulsen et al. 2012b). However, these experiments were performed using a281
real-time MLC tracking system, which is not possible with the Elekta system used282
here, and limited the success of the results presented in this paper. Keall et al.283
(2011) performed real-time dMLC IMAT (no dose rate or gantry speed modulation)284
tracking measurements of realistic lung traces with the Varian MLC tracking system,285
and found, on average, that 1.6% of points failed the 3%/3 mm gamma analysis with286
tracking. Additionally, they found no loss of treatment efficiency for the two lung287
plans investigated, but these were for IMAT plans without modulation of gantry speed288
and dose rate, whereas all plans used in the study presented here featured modulation289
of the gantry speed and dose rate. Zimmerman et al. (2009) have presented dMLC290
tracking results for one lung VMAT plan on a Varian accelerator, also using the Delta4291
detector, and showed an increase in the gamma-analysis pass rate from 87% without292
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tracking to 97% with tracking, but the efficiency of the treatment was not mentioned.293
Poulsen et al. (2012b) also demonstrated successful image-based MLC tracking of two294
lung VMAT plans with dose rate and gantry modulation on a Varian system (mean295
gamma pass rate of 98.3%), but again the efficiency was not mentioned. None of the296
measurements performed in the study in this paper achieved the same accuracy level for297
VMAT MLC tracking, although the mean gamma-analysis pass rate with 2D motion-298
compensation was on the border of clinical acceptability (Ezzell et al. 2009) for all time299
periods investigated. One of the contributing factors towards this result, was that it300
was only possible to transform the MLC leaf positions to follow a target motion at the301
control points (every 5 ◦ for these plans) and therefore the time interval at which the302
transformation took place varied with gantry speed. Such coarse and irregular sampling303
of the breathing cycle left a residual error between the position of the target and the304
transformed position of the MLC aperture, as between control points, the MLC motion305
was linear but the target motion, non-linear. It is possible to deliver a VMAT arc on306
Elekta linear accelerators with a finer control point spacing, e.g. 2 ◦, which has been307
shown theoretically to improve the accuracy of tracking compared with coarser control308
points (Davies et al. 2011). However, for this experimental study, plans of control309
point spacing 5 ◦ were used as the ability of the algorithm to correctly predict delivery310
parameters during a VMAT arc was shown to increase with increased control point311
spacing (Davies et al. 2011). The limitations of transforming the leaf positions only at312
the control points compromised the tracking accuracy the most for the trajectory with313
the shortest time period, and therefore the highest gamma-analysis pass rates were seen314
for the motion trajectory with 10 s time period, where the breathing cycle was sampled315
most frequently. However, as shown by Seppenwoolde et al. (2002) in an analysis of the316
characteristics of lung-tumour motion, the average time period is 3.6 s. Therefore, for317
accurate MLC tracking of realistic respiratory motion it would be desirable to be able to318
transform the leaf positions at a specified time interval, as seen in prototype real-time319
MLC tracking systems (Keall et al. 2006, Tacke et al. 2010), rather than be constrained320
solely to the control points.321
The tracking algorithm presented here reduces the dose rate until the MLC tracking322
plan is deliverable. However, Bedford & Warrington (2009) have shown that at low323
dose rates beam symmetry can be degraded, and recommend that dose rates less than324
1.25 MU s−1 should only be used for small fractions of the VMAT delivery. For the plans325
used in this study, the majority of the deliveries, both static-tumour and MLC tracking,326
were delivered at a dose rate greater than 3 MU s−1 with the lowest observed dose rate327
being 1.75 MU s−1 for the plans for patient 5, for a duration of approximately 10 MU.328
Therefore beam symmetry was not an issue in these experiments, but is something to329
be cautious of when implementing this algorithm.330
The main limitation of the algorithm used in this study, is the requirement for a331
priori knowledge of the patient’s respiratory motion. Respiration can be unpredictable332
(Seppenwoolde et al. 2002, Shirato et al. 2006), and therefore there could be difficulty333
in translating this algorithm to a clinical setting, where the motion may vary from that334
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seen during the radiotherapy planning process. It is possible to account for changes in335
breathing frequency using adaptive dose-rate regulation as demonstrated by Yi et al.336
(2008), which could be used to maintain synchronisation between the planned MLC337
motion (prescribed as a function of monitor units) and the tumour motion. However,338
amplitude variations and baseline shifts are more problematic, and difficult to correct339
with this method. The ideal solution to such a problem is detection of the motion in340
real-time and transformation of the MLC leaf positions accordingly, allowing pauses341
in the radiation beam if the tumour motion is too fast for the MLC leaves to track,342
as described by Sawant et al. (2008). However, real-time MLC tracking is not trivial;343
accounting for system latency and reliable detection of tumour position are some of the344
difficulties faced.345
The plans investigated in this study all had gantry speed and dose rate modulation,346
and the greatest increase in delivery time observed was 20%, and for three of the patients,347
there was a negligible increase in delivery time. The results therefore demonstrate348
that the Agility MLC has the potential to be a powerful and improved tool for MLC349
tracking due to its increased leaf and jaw speeds. Although the Agility MLC design350
has the additional benefit of the dynamic leaf guide, for this set of experiments and351
the VMAT plans selected, the DLG did not prove to be useful. Whether this is the352
case for all VMAT plans, or for other treatment modalities cannot be concluded from353
the experiments performed, and it is possible that for step-and-shoot IMRT delivery,354
or conformal delivery, the DLG would be a desirable feature for MLC tracking. It was355
not possible in this study to evaluate the dosimetric benefit of the thinner leaf width356
of the Agility compared with the MLCi multileaf collimator, but as shown by Poulsen357
et al. (2012b), the areas of underdose and overdose are directly correlated with the358
gamma-analysis pass rate, and therefore one would expect that an MLC with a thinner359
leaf width would be more suitable for MLC tracking, where it is often necessary to360
transform the MLC apertures parallel to the direction of leaf travel.361
Although the leaf speed of Agility MLC is one of the fastest commercially available,362
it should be noted that this increased speed enables greater leaf shifts which, if justified,363
must be modelled correctly in the treatment planning process. As illustrated in a review364
by Yu & Tang (2011), plans with longer leaf travel can result in greater discrepancies365
between the planned and delivered dose, and therefore it is vital that sufficient beam366
sampling is allowed in the dose calculation to ensure that the treatment planning system367
calculation is representative of the planned delivery.368
5. Conclusion369
An algorithm for MLC tracking VMAT delivery on Elekta linear accelerators has been370
experimentally validated for the Agility MLC with the Integrity 3.0 control system, and371
dosimetric measurements have been performed to evaluate the accuracy of MLC tracking372
with this technique. It has been shown that an a priori method can offer accurate and373
efficient motion-compensation, with the majority of MLC tracking deliveries carried374
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out with a modest, or zero, time increase compared with the static-tumour delivery.375
However, a real-time system is necessary for increased accuracy and to take full376
advantage of the Agility MLC’s capabilities.377
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